Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.

ABSTRACT: Imatinib (IMA) therapy for paediatric chronic myeloid leukemia (pCML) requires age-dependent dose adjustments. Assessment of therapeutic drug monitoring (TDM) under 'real-world' conditions was performed. Collection of blood and TDM-relevant data, calculation of individual dosage exposure, measurement of plasma C_min (IMA, Nor-IMA) by HPLC/MS-MS and recording of adverse event (AE). Two hundred and forty-six specimens from 66 patients were analysed. Individual median IMA dosage exposure was 253 mg/m² (range: 128-504). Children <13 years received a median of 43 mg/m² more than older patients (p < 0.0001). Median C_min of IMA and Nor-IMA was 1017 ng/mL (range: 51-3976) and 269 ng/mL (range: 21-981), respectively, correlating significantly with the pres

SUBMITTER: Suttorp M 

PROVIDER: S-EPMC12078881 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature